CDC42 and myeloproliferative disorder: This was recapitulated in MPN mice, with PV-like (but not ET-like) mice showing increased BM type III collagen content at the early disease stage; this was reverted by ruxolitinib and a similar trend was observed after CDC42 inhibition (Extended Data Fig. 9a,b).